UROTHELIAL CARCINOMA

This study followed 596 adults in France with advanced or metastatic urothelial carcinoma (a type of bladder cancer) who were given avelumab as a maintenance treatment after initial chemotherapy. The goal was to see how long patients lived and how the drug performed in everyday m…

This study tested a new drug called CBX-12 in 69 adults with advanced solid tumors (like ovarian, lung, or breast cancer) that had stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors. The study was completed, but res…

This early-phase study tested a combination of two drugs—avelumab (an immunotherapy) and docetaxel (a chemotherapy)—in 21 people with advanced bladder cancer that had stopped responding to standard platinum-based chemo or could not take it. The main goals were to find safe doses …

This early-phase study tested a new drug called TPST-1495, alone or with pembrolizumab, in 89 people with advanced solid tumors (like colorectal, lung, or head and neck cancer) that had stopped responding to standard treatments. The main goal was to find the safest dose and check…

This study tested a combination of two drugs (toripalimab and gemcitabine) given before surgery to people with muscle-invasive bladder cancer who cannot take the standard chemotherapy drug cisplatin. The goal was to see how well the drugs shrink tumors before the bladder is remov…

This study tested whether adding lenvatinib to pembrolizumab (immunotherapy) helps people with advanced bladder cancer who cannot receive standard platinum chemotherapy. About 505 participants received either the combination or pembrolizumab alone. The study was stopped early bas…

This study tested a drug called sacituzumab govitecan in 44 people with muscle-invasive bladder cancer who could not take or refused standard cisplatin chemotherapy. The drug was given before surgery to remove the bladder, aiming to wipe out all cancer cells. The main goal was to…

This early-stage trial tested a new treatment for people with bladder, skin, or head and neck cancers that have a specific marker called MAGE-A10. Doctors took patients' own immune cells, modified them in a lab to better attack cancer, and gave them back after a short course of c…

This study tested several immunotherapy drug combinations in 272 people with advanced bladder cancer that had worsened after standard chemotherapy. The goal was to see if these combinations could shrink tumors or slow the disease. Participants could switch to a different combinat…

This study looked at whether a urine test called Cxbladder can accurately detect bladder cancer in people who have blood in their urine (hematuria). Researchers compared the test results to the standard method, cystoscopy (a camera inside the bladder), in 682 veterans. The goal w…

This study tested whether a simple, non-invasive breath test can predict if cancer patients will benefit from immunotherapy drugs. Researchers analyzed the breath of 190 adults with lung, melanoma, bladder, kidney, or head and neck cancers to see if unique chemical patterns could…

This study explored whether the proteins from gut bacteria differ between bladder cancer patients who respond to immunotherapy and those who do not. Researchers collected stool and blood samples from 40 patients to compare these protein profiles. The goal was to find a way to pre…